Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Share-based Compensation (2020 - 2025)

Barinthus Biotherapeutics' Share-based Compensation history spans 6 years, with the latest figure at $696000.0 for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 7.81% year-over-year to $696000.0; the TTM value through Dec 2025 reached $468000.0, down 90.06%, while the annual FY2025 figure was $468000.0, 90.06% down from the prior year.
  • Share-based Compensation reached $696000.0 in Q4 2025 per BRNS's latest filing, up from -$415000.0 in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $8.7 million in Q2 2021 to a low of -$415000.0 in Q3 2025.
  • Average Share-based Compensation over 5 years is $1.8 million, with a median of $1.2 million recorded in 2024.
  • Peak YoY movement for Share-based Compensation: skyrocketed 2090.91% in 2021, then plummeted 136.28% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $3.6 million in 2021, then crashed by 42.99% to $2.0 million in 2022, then tumbled by 61.49% to $786000.0 in 2023, then dropped by 3.94% to $755000.0 in 2024, then decreased by 7.81% to $696000.0 in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Share-based Compensation are $696000.0 (Q4 2025), -$415000.0 (Q3 2025), and -$281000.0 (Q2 2025).